Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial

(2015) Stephen J. Nicholls et al.   AMERICAN HEART JOURNAL

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

(2015) Dean J. Kereiakes et al.   AMERICAN HEART JOURNAL

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

(2015) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

State of the art paper Lipid-lowering therapy in older persons

(2015) Wilbert S. Aronow   Archives of Medical Science

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES

(2015) Erin A. Bohula et al.   CIRCULATION

Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials

(2015) Costas Thomopoulos et al.   CLINICAL CARDIOLOGY

Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

(2015) Eli M. Roth et al.   CLINICAL THERAPEUTICS

Targeting PCSK9 for Therapeutic Gains

(2015) Michael D. Shapiro et al.   Current Atherosclerosis Reports

Should we consider ezetimibe to reach even lower LDL-C targets?

(2015) Aris P. Agouridis et al.   CURRENT MEDICAL RESEARCH AND OPINION

Using the concept of ideal cardiovascular health to measure population health

(2015) Laura C. Maclagan et al.   CURRENT OPINION IN CARDIOLOGY

Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort

(2015) Henna Cederberg et al.   DIABETOLOGIA

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

(2015) Yuichi J. Shimada et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology

(2015) Michael M Page et al.   Expert Opinion on Drug Metabolism & Toxicology

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Expert Opinion On Drug Safety

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials

(2015) Chi-kin Ip et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Atherosclerosis: Recent trials, new targets and future directions

(2015) Ricardo Ladeiras-Lopes et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Safety and efficacy of ezetimibe: A meta-analysis

(2015) Gianluigi Savarese et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

New Therapies in the Treatment of High Cholesterol

(2015) William H. Shrank et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease

(2015) Ankur Pandya et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events

(2015) Amit Pursnani et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Application of New Guidelines for the Primary Prevention of Atherosclerotic Cardiovascular Disease in a Korean Population

(2015) Nan Hee Kim et al.   Journal of Atherosclerosis and Thrombosis

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

(2015) Harold Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study

(2015) Seyed Saeed Hashemi Nazari et al.   Journal of Clinical Lipidology

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

(2015) Eliot A. Brinton et al.   Journal of Clinical Lipidology

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention

(2015) Kenichi Tsujita et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both

(2015) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Ezetimibe Stimulates Intestinal Glucagon-Like Peptide 1 Secretion Via the MEK/ERK Pathway Rather Than Dipeptidyl Peptidase 4 Inhibition

(2015) Eugene Chang et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipids, blood pressure and kidney update 2014

(2015) Maciej Banach et al.   PHARMACOLOGICAL RESEARCH

PCSK9 inhibition in patients with hypercholesterolemia

(2015) Nihar R. Desai et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

(2015) Jennifer G. Robinson et al.   CLINICAL CARDIOLOGY

Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy

(2014) Kimberly A. Gudzune et al.   ANNALS OF INTERNAL MEDICINE

Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia

(2014) Anastazia Kei et al.   Archives of Medical Science

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

(2014) Helen M Colhoun et al.   BMC Cardiovascular Disorders

Antihyperlipidemic Therapies Targeting PCSK9

(2014) Michael Weinreich et al.   Cardiology in Review

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies

(2014) John J. P. Kastelein et al.   CARDIOVASCULAR DRUGS AND THERAPY

Dysfunctional HDL: the journey from savior to slayer

(2014) Corina Serban et al.   Clinical Lipidology

Can We Change the Functionality of HDL Cholesterol with Nonpharmacological and Pharmacological Agents?

(2014) S. Dragan et al.   CURRENT MEDICINAL CHEMISTRY

Statins and New-Onset Diabetes

(2014) Marcin Barylski et al.   CURRENT PHARMACEUTICAL DESIGN

Evolving targets for lipid-modifying therapy

(2014) R. Q. Do et al.   EMBO Molecular Medicine

Letter to the Editor Atorvastatin in combination with ezetimibe and carotid atherosclerosis

(2014) K.I. Paraskevas et al.   GENETICS AND MOLECULAR RESEARCH

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

(2014) Eli M. Roth et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort

(2014) Maryam Kavousi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Proprotein Convertase Subtilisin/Kexin 9 Inhibitors

(2014) Simona Dragan et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

(2014) Terry A. Jacobson et al.   Journal of Clinical Lipidology

Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum

(2014) Małgorzata Myśliwiec et al.   Journal of Clinical Lipidology

Application of New Cholesterol Guidelines to a Population-Based Sample

(2014) Michael J. Pencina et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients

(2014) D. Keene et al.   BMJ-British Medical Journal

Impact on Optical Coherence Tomographic Coronary Findings of Fluvastatin Alone Versus Fluvastatin + Ezetimibe

(2013) Maoto Habara et al.   AMERICAN JOURNAL OF CARDIOLOGY

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia

(2013) Mukul Sharma et al.   ANNALS OF INTERNAL MEDICINE

Lipid-Lowering Therapy in Persons With Chronic Kidney Disease

(2013) Ashish Upadhyay et al.   ANNALS OF INTERNAL MEDICINE

State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease

(2013) Beata Franczyk-Skóra et al.   Archives of Medical Science

Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study

(2013) Vasilios G. Athyros et al.   Archives of Medical Science

Persistence with statin therapy in Hungary

(2013) Zoltan Kiss et al.   Archives of Medical Science

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia

(2013) Michael J. Koren et al.   CIRCULATION

The Role of Fibrate Treatment in Dyslipidemia: An Overview

(2013) Niki Katsiki et al.   CURRENT PHARMACEUTICAL DESIGN

PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?

(2013) Maciej Banach et al.   CURRENT PHARMACEUTICAL DESIGN

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

(2013) Manfredi Rizzo et al.   CURRENT PHARMACEUTICAL DESIGN

American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

(2013) Paul Jellinger et al.   Endocrine Practice

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

More Than a Billion People Taking Statins?

(2013) John P. A. Ioannidis   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients

(2013) Subroto Acharjee et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

An International Model to Predict Recurrent Cardiovascular Disease

(2012) Peter W.F. Wilson et al.   AMERICAN JOURNAL OF MEDICINE

Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets

(2012) Manfredi Rizzo et al.   Archives of Medical Science

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials

(2012) Doralisa Morrone et al.   ATHEROSCLEROSIS

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

(2012) David Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease

(2012) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

(2012) Michael J Koren et al.   LANCET

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

(2012) Robert P Giugliano et al.   LANCET

Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

(2012) Aneta Otocka-Kmiecik et al.   PROGRESS IN LIPID RESEARCH

Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

(2011) Uchechukwu K. Sampson et al.   Current Atherosclerosis Reports

Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?]

(2011) Kosmas I. Paraskevas et al.   Current Vascular Pharmacology

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals

(2011) Christiane L. Haase et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin

(2011) David D. Waters et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

(2011) Colin Baigent et al.   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

(2010)   LANCET

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

(2009) Allen J. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease

(2008) Ruth Frikke-Schmidt   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis

(2008) Anne B. Rossebø et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia

(2008) John J.P. Kastelein et al.   NEW ENGLAND JOURNAL OF MEDICINE